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Abstract: The new category of MiT family translocation renal cell carcinoma has been included into
the World Health Organization (WHO) classification in 2016. The MiT family translocation renal
cell carcinoma comprises Xp11 translocation renal cell carcinoma harboring TFE3 gene fusions and
t(6;11) renal cell carcinoma harboring TFEB gene fusion. At the beginning, they were recognized in
childhood; nevertheless, it has been demonstrated that these neoplasms can occur in adults as well.
In the nineties, among Xp11 renal cell carcinoma, ASPL, PRCC, and SFPQ (PSF) were the first genes
recognized as partners in TFE3 rearrangement. Recently, many other genes have been identified,
and a wide spectrum of morphologies has been described. For this reason, the diagnosis may be
challenging based on the histology, and the differential diagnosis includes the most common renal cell
neoplasms and pure epithelioid PEComa/epithelioid angiomyolipoma of the kidney. During the last
decades, many efforts have been made to identify immunohistochemical markers to reach the right
diagnosis. To date, staining for PAX8, cathepsin K, and melanogenesis markers are the most useful
identifiers. However, the diagnosis requires the demonstration of the chromosomal rearrangement,
and fluorescent in situ hybridization (FISH) is considered the gold standard. The outcome of Xp11
translocation renal cell carcinoma is highly variable, with some patients surviving decades with
indolent disease and others dying rapidly of progressive disease. Despite most instances of t(6;11)
renal cell carcinoma having an indolent clinical course, a few published cases demonstrate aggressive
behavior. Recently, renal cell carcinomas with TFEB amplification have been described in connection
with t(6;11) renal cell carcinoma. Those tumors appear to be associated with a more aggressive clinical
course. For the aggressive cases of MiT family translocation carcinoma, the optimal therapy remains
to be determined; however, new target therapies seem to be promising, and the search for predictive
markers is mandatory.
Keywords: MiT family translocation renal cell carcinoma; Xp11 translocation renal cell carcinoma;
t(6;11) translocation renal cell carcinoma; FISH; TFE3; TFEB; TFEB-amplified renal cell carcinoma
1. Xp11 Translocation Renal Cell Carcinoma
Xp11 translocation renal cell carcinoma is a distinctive subtype of renal cell carcinoma, characterized
by several chromosomal translocations involving the TFE3 gene, located on chromosome Xp11.2.
In these tumors, the TFE3 transcription factor gene is fused by translocation to one of several other
genes [1–9]:
• t(X;1) (p11.2;q21.2) gene PRCC
• t(X;17) (p11.2;q25) gene ASPL (ASPSCR1)
• t(X;1) (p11.2;p34) gene SFPQ (PSF)
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• t(X;17) (p11.2;q23) gene CLTC
• t(X;3) (p11.2;q21) gene PARP14
• t(X;10) (11.2;q23) unknown gene
• t(X;17) (p11.2;q21.33) gene LUC7L3
• t(X;19) (p11.2;q13.3) gene KHSRP
• t(X;17) (p11.2;p13) gene DVL2
• t(X;22) (p11.2;q11.21) gene MED15
• t(X;6) (p11.2;q25.3) gene ARIDB
• t(X;5) (p11.2;q31.2) gene MATR3
• t(X;1) (p11.2;p31.1) gene FUBP1
• t(X;11) (p11.2;q13.1) gene NEAT1
• t(X;10) (p11.2;q22.2) gene KAT6B
• inv (X) (p11.2;q12) gene NONO (p54nrb)
• inv(X) (p11.2;p11.3) gene RBM10
• inv(X) (p11.23;p11.23) il gene GRIPAP1
The three most common Xp11 translocation renal cell carcinomas are those bearing the t(X;1)
(p11.2;q21) which fuses the PRCC and TFE3 genes, the t(X;17) (p11.2;q25) which fuses the ASPL and
TFE3 genes, and the t(X;1) (p11.2;p34) which fuses the SFPQ (PSF) and TFE3 genes [10]. Interestingly,
t(X;17) renal cell carcinoma or alveolar soft part sarcoma harbor the same ASPL-TFE3 fusion gene [11].
However, the translocation is balanced in t(X;17) renal cell carcinoma and unbalanced in alveolar soft
part sarcoma, which presumably explains the clinical and morphological differences. The function
of chimeric TFE3 fusion proteins can also vary, which may explain the different histological features
observed in this tumor entity of renal cell carcinoma.
1.1. Clinical Features
Xp11 translocation renal cell carcinoma comprises 20–75% of renal cell carcinomas in childhood [12]
and 1–4% of adult renal cell carcinomas (calculated excluding patients younger than 18 years old) with
an average age of onset of 40 years (Figure 1). The incidence of Xp11 translocation renal cell carcinoma
in adults may be underestimated, likely for the morphological overlap with more common adult
renal cell carcinoma subtypes, such as clear cell and papillary renal cell carcinoma. Considering an
overall of 403 genetically confirmed Xp11 translocation renal cell carcinomas described in the literature,
there is a slight female predominance (F:M ratio, 1.6:1). Clinically, there are no particular features
typically presented. As other renal cell carcinomas, roughly one-third of all tumors are asymptomatic,
often accidentally discovered. Prior exposure to cytotoxic chemotherapy has been reported as a risk
factor [13].
Figure 1. Cont.
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Figure 1. A chart showing the incidence (number of patients with tumors divided by the number of
patients in the age group) of Xp11 translocation renal cell carcinomas (A) and t(6;11) renal cell carcinoma
(C) at different ages. A chart showing the clinical behavior of Xp11 translocation renal cell carcinomas
(B) and t(6;11) renal cell carcinoma (D) at different ages.
1.2. Pathologic Features
1.2.1. Gross Findings
They usually present as solitary cortical masses characterized by tan-yellow cut surfaces with foci
of hemorrhage and necrosis and occasionally focal cystic degeneration. Although there is no specific
macroscopic appearance of Xp11 translocation renal cell carcinoma, they do not share the macroscopic
features of clear cell renal cell carcinoma.
1.2.2. Microscopic Features
Histologically, Xp11 translocation renal cell carcinomas are characterized by heterogeneous
architectural and cytologic features, mimicking almost all subtypes of renal cell carcinoma [10,14].
The most distinctive morphologic pattern is the presence of a papillary architecture composed of
epithelioid clear cells. However, different architectures have been reported, such as solid, nested,
trabecular, and microcystic pattern. More frequently, tumor cells demonstrate voluminous clear to
eosinophilic cytoplasm (Figure 2). The nuclei may show variability in size and are generally large
with a prominent eosinophilic nucleolus (typically G3 by ISUP/WHO 2016) [1]. Psammoma bodies are
often present.
1.2.3. Immunohistochemical Features and Fluorescent in Situ Hybridization (FISH) Analysis
Like other subtypes of renal cell carcinoma, Xp11 translocation renal cell carcinomas are
positive for PAX8. Vimentin and cytokeratin 7 (CK7) are typically negative. Staining for CD10
and alpha-methylacyl-CoA racemase (AMACR) is generally reported. In one-third of all cases,
Xp11 translocation renal cell carcinoma focally express melanogenic markers such as Melan-A and
HMB45. Staining for cathepsin K is observed in a subset of Xp11 translocation renal cell carcinomas
(approximately 50%) (Figure 2). Interestingly, PRCC-TFE3 renal cell carcinoma is labelled more
frequently for cathepsin K than ASPL-TFE3 renal cell carcinoma [15,16]. TFE3 immunostaining,
initially considered as the most sensitive and specific marker, should be cautiously used due to the not
infrequent false-positive and false-negative results [17]. For this reason, the identification of the TFE3
rearrangement by FISH assays on formalin-fixed and paraffin-embedded tissue sections is currently
the gold standard to reach the correct diagnosis [17–19]. Of course, a reliable interpretation requires
a univocal cut-off. However, different thresholds have been used to demonstrate the occurrence
of translocation. A positive result was considered when >10%, >15%, or >20% of the neoplastic
nuclei showed split signals. Nevertheless, an extensive review of previously reported cases of Xp11
translocation renal cell carcinoma in which it has been reported that the frequency of split signals in
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each case showed a high frequency of split signals (>40%). It is important to keep in mind that the FISH
assay is unable to detect subtle TFE3 gene inversions, such as those that result in the RBM10-TFE3 gene
fusion [20]. In the experience of the authors, minimally split fluorescent signals in which fluorescent
signals were separated by a signal diameter or less were observed in few cases [21]. Recently, it has
been argued whether TFE3 gene rearrangement is the key event in tumorigenesis [22–24]. In our
practice, the fraction of cells showing the translocation is commonly high, supporting the idea that it is
the main driver event in tumorigenesis.
Figure 2. Different morphologies of Xp11 translocation renal cell carcinomas: resembling a clear
cell renal cell carcinoma (Magnification: 200×) (A), showing a papillary (Magnification: 25×) (C) or
cystic (Magnification: 100×) (E) pattern. An example of strong and diffuse expression of cathepsin K
(Magnification: 200×) (B), the nuclear positivity of PAX8 (Magnification: 25×) (D), and the demonstration
of TFE3 gene rearrangement by FISH (Magnification: 1000×) (F).
1.3. Differential Diagnosis
Due to the wide spectrum of morphologies observed in Xp11 translocation renal cell carcinomas,
the differential diagnosis is challenging, and it is important to consider these carcinomas in all unusual
renal cell carcinomas occurring, especially in children and young adults [1]. Several neoplasms
can be confused with Xp11 translocation renal cell carcinoma, mainly clear cell and papillary renal
cell carcinomas. In this setting, cathepsin K is the most reliable immunohistochemical marker.
Of note, as previously stated, immunolabelling for cathepsin K is observed in roughly half of all Xp11
translocation renal cell carcinomas. Other immunohistochemical markers may be helpful based on
the differential diagnosis. CD10 is expressed in almost all Xp11 translocation renal cell carcinomas
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in analogy to clear cell renal cell carcinomas. However, carbonic anhydrase IX is usually negative or
only focally present in Xp11 translocation renal cell carcinomas and positive in clear cell renal cell
carcinomas, suggesting the usefulness of this marker in this particular differential diagnosis. On the
other hand, AMACR (Alpha-methylacyl-CoA racemase) is frequently positive in Xp11 translocation
renal cell carcinomas, as well as in papillary renal cell carcinomas, but CK7 is typically negative in Xp11
translocation renal cell carcinomas and positive in papillary renal cell carcinomas. Clear cell papillary
renal cell carcinomas may be another tricky differential diagnosis [25]. Those tumors usually label for
CK7 and GATA3, both not expressed in Xp11 translocation renal cell carcinomas. Finally, it is important
to remember less frequent tumors, such as pure epithelioid PEComa/epithelioid angiomyolipoma.
In those cases, PAX8 and CD68 (PG-M1) are extremely useful (see differential diagnosis of t(6;11) renal
cell carcinomas).
1.4. Prognosis and Treatment
The outcome of Xp11 translocation renal cell carcinoma is highly variable, from indolent to rapidly
aggressive behavior [12,26,27]. Overall, Xp11 translocation renal cell carcinoma has a worse prognosis
than papillary renal cell carcinoma and there is a similar prognosis for clear cell renal cell carcinoma [28].
Although several studies have claimed that Xp11 translocation renal cell carcinomas in children have a
relatively indolent course, the review of the literature (Figure 1) shows a high percentage of aggressive
cases in young adults. Among Xp11 translocation renal cell carcinoma, patients with ASPL-TFE3 fusion
seem to have a worse prognosis and more frequently lymph node metastasis, but it is still unclear
whether the fusion partner plays a prognostic role [28,29]. Considering an overall 403 genetically
confirmed Xp11 translocation renal cell carcinomas described in the literature, 47% of cases (91 of
194 tumors with available follow up) behaved aggressively. When aggressive and non-aggressive cases
are compared, we observe that recurrences or metastases occurred within 24 months from the surgery.
It is worth noting that sarcomatoid or rhabdoid de-differentiation have never been reported. There is
no statistical difference of age between aggressive and non-aggressive cases. As expected, a larger
tumor size (p < 0.0001) correlates with aggressive behavior. Interestingly, the presence of necrosis,
but not nucleolar grade, correlates with aggressiveness, the same prognostic characteristics reported in
chromophobe renal cell carcinoma.
With regard to the treatment, the optimal therapy for MiT family translocation renal cell carcinoma
remains to be determined. For localized tumors, including patients with positive regional lymph
nodes, surgery is the treatment of choice. For patients with hematogenous metastases, several attempts
of therapy have been tried based on the treatment of clear cell renal cell carcinoma. Therapies targeting
vascular endothelial growth factor receptor, immunotherapy, mTOR inhibitors, and target therapies
for the MET signaling pathway are possible options [30–34]. Unfortunately, to date there is no data
regarding predictive markers to choose the best therapy for an individual patient. In the past few years,
the efficacy of Cabozantinib, a tyrosine kinase inhibitor with activity against c-MET, AXL, and vascular
endothelial growth factor receptor 2, has been proven for the treatment of metastatic clear cell renal cell
carcinomas [35,36] and recently for non-clear cell histologies [37]. Moreover, whole genome DNA and
RNA sequencing studies have recently been reported on a small number of cases [10,38], providing the
activity of other pathways which may present other potential targets for novel therapies [38].
2. t(6;11) Renal Cell Carcinoma
t(6;11) renal cell carcinoma is an extremely rare variant and accounts for 0.02% of all renal
carcinomas. Although the initial description was in children [39], t(6,11) renal cell carcinoma may
occur in adults. The t(6;11) translocation fuses the gene for TFEB, located on chromosome 6, with
Alpha (MALAT1), a gene of unknown function, resulting in overexpression of TFEB.
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2.1. Clinical Features
The t(6;11) renal cell carcinomas are less common than the Xp11 renal cell carcinomas;
approximately 60 cases are documented in the literature, the majority of which in children and
adolescents. However, it has been demonstrated that these neoplasms can occur in adults as well.
The mean age of presentation is 34 years (Figure 1), with a wide reported range of 3–77 years.
Conversely to Xp11 translocation renal cell carcinomas, in t(6;11) renal cell carcinoma there is no
gender predominance (F:M ratio, 0.75:1). The tumor is usually an incidental finding. Similar to
Xp11 translocation renal cell carcinoma, a subset of cases has occurred in patients who have received
cytotoxic chemotherapy for other reasons.
2.2. Pathologic Features
2.2.1. Gross Findings
As Xp11 translocation renal cell carcinoma, t(6;11) renal cell carcinoma does not have a distinctive
gross appearance.
2.2.2. Microscopic Features
Histologically, t(6;11) renal cell carcinoma has been classically characterized by a distinctive
biphasic morphology with larger epithelioid cells and smaller cells clustered around eosinophilic
spheres formed by basement membrane material (Figure 3) [1,40]. However, several reports have shown
a broad range of morphology in molecularly confirmed t(6;11) renal cell carcinomas [41]. Papillary
and tubulocystic architectures, clear cell and oncocytoma-like features, and diffuse hyalinization with
thick-walled blood vessels are some of the unusual pathological features described [1]. The cells
typically show nucleolar grade G2 and G3 by ISUP/WHO 2016 [42].
Figure 3. The most common morphology of t(6;11) renal cell carcinoma with larger epithelioid cells
and smaller cells clustered around eosinophilic spheres formed by basement membrane material
(A, Magnification: 25×; B, Magnification: 200×). Almost all cases are positive for cathepsin K
(Magnification: 200×) (C) and HMB45 (Magnification: 200×) (D).
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2.2.3. Immunohistochemical Features and FISH Analysis
Immunohistochemically, most t(6;11) renal cell carcinomas express PAX8, supporting renal tubular
differentiation and melanogenesis markers, such as HMB-45 and Melan-A. Cathepsin K is overexpressed
in almost all t(6;11) renal cell carcinomas [43,44]. Staining for TFEB was considered highly sensitive and
specific for this tumor. However, the results can be inconsistent among laboratories, mainly because of
technical factors such as fixation time and differences in the methods of antigen retrieval. Like Xp11
translocation renal cell carcinomas, the identification of the rearrangement by FISH analysis is the gold
standard for the diagnosis [45]. As previously discussed for Xp11 translocation renal cell carcinomas, it is
of paramount importance to define a proper cut-off to establish the occurrence of TFEB rearrangement,
even in t(6;11) renal cell carcinoma, when the frequency of split signals is high (>38%). Although less
frequently than in Xp11 translocation renal cell carcinoma, we observed minimally split fluorescent signals.
2.3. Differential Diagnosis
The wide spectrum of morphology results in several differential diagnoses including Xp11
translocation renal cell carcinoma, pure epithelioid PEComa/epithelioid angiomyolipoma, and other
more common types of renal cell carcinoma [46–48]. Among them, pure epithelioid PEComa/epithelioid
angiomyolipoma is the most challenging diagnosis in clinical practice [42]. Indeed, the two entities
share the immunohistochemical expression of melanogenesis markers and cathepsin K, and both are
often negative for cytokeratin. PAX8 immunoreactivity and CD68 (PG-M1) negativity supports the
diagnosis of t(6;11) renal cell carcinoma, whereas pure epithelioid PEComa/epithelioid angiomyolipoma
is PAX8 negative and CD68 (PG-M1) positive [42].
2.4. Prognosis and Treatment
Most instances of t(6;11) renal cell carcinoma have an indolent clinical course. An aggressive
behavior is observed in roughly 17% of the cases (11 of 64 tumors with available follow up). Larger
masses (p = 0.04) and older patients (p = 0.007) seem to be parameters correlated with aggressiveness.
It should be noted that hematogenous metastases seem to be more common than nodal metastases.
To date, there are no well-established prognostic markers to predict the biological behavior. However,
it is possible that an increase in the copy number of the TFEB gene region in t(6;11) renal cell carcinoma
may predict an aggressive clinical course [42,49]. The radical surgery remains the best therapeutic
strategy. Because of the rarity of this tumor, no information regarding neoadjuvant or adjuvant
therapies are available. Since these neoplasms have demonstrated the capacity to recur, follow-up
examinations are important for these patients.
3. Renal Cell Carcinoma with TFEB Amplification
More recently, renal cell carcinomas with TFEB amplification have been described and appear
to be associated with a poor outcome [50–55]. TFEB amplification in renal cell carcinoma
can occur independently of or in association with TFEB rearrangement [50,55]. TFEB gene
rearrangement or amplification increases TFEB expression which causes the subsequent expression
of immunohistochemical markers such as cathepsin K, Melan-A, and HMB45 [43]. Nevertheless,
TFEB-amplified renal cell carcinomas are different from t(6;11) renal cell carcinomas [50]. First, they
typically occur in older patients (mean 65 years) compared to unamplified t(6;11) renal cell carcinoma
(mean age 34 years). Second, their morphology is usually high grade and less typical than the biphasic
appearance of t(6;11) renal cell carcinoma (Figure 4). Third, melanogenic marker expression is less
reliable: while all cases have expressed Melan-A, roughly half of the cases express cathepsin K and
HMB45, usually positive in t(6;11) renal cell carcinoma. Fourth, TFEB amplified renal cell carcinomas
typically have a poor outcome while t(6;11) renal cell carcinomas are usually indolent. Of note, it has
been demonstrated that renal cell carcinomas showing TFEB amplification harbor concurrent vascular
endothelial growth factor A (VEGFA) gene amplification [52,55]. This is may be due to the proximity
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of those two genes, which are both located on the short arm of chromosome 6. With regard to the
treatment, Gupta et al. hypothesized the possible usefulness of VEGFR-targeted therapy in a few cases
of renal cell carcinomas with TFEB/VEGFA coamplification [52].
Figure 4. A high-grade renal cell carcinoma (A, Magnification: 50×; B, Magnification: 200×) expressing
Melan-A (Magnification: 400×) (C) and showing TFEB gene amplification by FISH (Magnification:
1000×) (D).
4. Comparison of Xp11 Translocation Renal Cell Carcinoma and t(6;11) Renal Cell Carcinoma
As illustrated in Table 1, Xp11 translocation renal cell carcinoma and t(6;11) renal cell carcinoma
differ in several ways. Xp11 translocation renal cell carcinoma seems to occur in patients younger
than t(6;11) renal cell carcinoma; with a slight female predominance and a more frequently aggressive
clinical course. Conversely to Xp11 translocation renal cell carcinoma, the immunohistochemical
analysis of t(6;11) renal cell carcinoma is more consistent, showing the overexpression of cathepsin K
and melanogenesis makers in almost all cases.
Table 1. Main differences between Xp11 translocation renal cell carcinoma and t(6;11) renal cell carcinoma.
Parameter Xp11 Translocation RCC t(6;11) RCC
Clinical
Age distribution peak: 20–29 years peak: 30–39 years
Gender F:M ratio, 1.6:1 F:M ratio, 0.75:1
Behavior aggressive in 47% of cases aggressive in 17% of cases
Morphology
features broad spectrum usually biphasic
Immunohistochemistry
Cathepsin K 47% positive 94% positive
Melan-A 39% positive 91% positive
HMB45 32% positive 83% positive
RCC: renal cell carcinoma; F: female; M: male.
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5. Conclusions
On the basis of their clinical, immunohistochemical, and molecular similarities, the last WHO
classification grouped Xp11 translocation renal cell carcinoma and t(6;11) renal cell carcinoma together
under the name “MiT family translocation renal cell carcinoma”. However, among them there are
few differences, mainly in morphology and clinical behavior. For those reasons, we suggest to keep
the distinction in the clinical practice. Overall, this review emphasizes that MiT family translocation
renal cell carcinoma is a distinctive entity and therefore stresses the importance of recognizing it as a
specific category of renal cell carcinoma to properly identify these cases in future clinical trials looking
for effective therapies.
Funding: This research received no external funding.
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